



AUG 2 0 2002

FORM PTOL 449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

RECEIVED

SEP 06 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
MB	A	0	0	1	9	0	4	8	02/14/02	Berenson	435	372	05/24/01
	B	0	0	3	1	2	5	3	10/18/01	Gruenberg	424	93.1	04/02/01
	C	0	0	5	3	3	6	1	12/20/01	Thompson <i>et al.</i>	424	143.1	06/07/95
	D	3	8	2	1	0	8	7	6/28/74	Knazek <i>et al.</i>	195	127	5/18/72
	E	3	8	8	3	3	9	3	5/13/75	Knazek <i>et al.</i>	195	1.8	2/11/74
	F	3	9	9	7	3	9	6	12/14/76	Delente	195	1.8	7/02/73
	G	4	0	8	7	3	2	7	5/02/78	Feder <i>et al.</i>	195	1.7	4/12/76
	H	4	2	0	0	6	8	9	4/29/80	Knazek <i>et al.</i>	435	2	8/29/78
	I	4	2	0	6	0	1	5	6/03/80	Knazek <i>et al.</i>	435	2	8/29/78
	J	4	2	2	0	7	2	5	09/02/80	Knazek <i>et al.</i>	435	285	4/03/78
	K	4	3	0	1	2	4	9	11/17/81	Markus <i>et al.</i>	435	235	7/23/80
	L	4	3	9	1	9	1	2	7/5/83	Yoshida <i>et al.</i>	435	241	9/18/80
	M	4	5	4	6	0	8	3	10/08/85	Meyers <i>et al.</i>	435	240	4/22/83
	N	4	6	2	9	6	8	6	12/16/86	Gruenberg	435	1	06/14/82
	O	4	6	9	0	9	1	5	09/01/87	Rosenberg	514	2	08/08/85
	P	4	7	2	2	9	0	2	02/02/88	Harm <i>et al.</i>	435	284	11/04/85
	Q	4	8	0	4	6	2	8	02/14/89	Cracauer <i>et al.</i>	435	240.242	08/19/87
	R	4	8	0	8	1	5	1	02/28/89	Dunn, Jr. <i>et al.</i>	604	6	04/27/87
	S	4	8	4	9	3	2	9	07/18/89	Leung <i>et al.</i>	435	2	04/20/87
	T	4	8	6	1	5	8	9	08/29/89	Ju	424	93	03/23/87
	U	4	8	9	4	3	4	2	01/16/90	Guinn <i>et al.</i>	435	291	09/22/86
	V	4	9	3	7	0	7	1	06/26/90	Cioco <i>et al.</i>	424	85.2	12/29/87
	W	4	9	7	1	7	9	5	11/20/90	Longenecker <i>et al.</i>	424	93	07/21/88
MB	X	4	9	7	3	5	5	8	11/27/90	Wilson <i>et al.</i>	435	240.242	04/28/88

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
M/B	Y	4	9	9	9	2	9	8	03/12/91	Wolfe <i>et al.</i>	435	240.242	04/27/88
	Z	5	0	0	2	8	7	9	03/26/91	Bowlin <i>et al.</i>	435	71.1	12/05/89
	AA	5	0	1	5	5	8	5	05/14/91	Robinson	435	240.242	02/23/88
	AB	5	0	4	1	2	8	9	08/20/91	Phillips <i>et al.</i>	424	85.2	11/13/87
	AC	5	0	5	7	4	2	3	10/15/91	Hiserodt <i>et al.</i>	435	240.23	12/18/87
	AD	5	0	6	1	6	2	0	10/29/91	Tsukamoto <i>et al.</i>	435	7.21	03/30/90
	AE	5	0	6	4	7	6	4	11/12/91	Besnainon <i>et al.</i>	435	285	12/19/89
	AF	5	0	8	1	0	2	9	01/14/92	Zarling <i>et al.</i>	435	172.3	02/01/89
	AG	5	1	2	3	9	0	1	06/23/92	Carew	604	5	
	AH	5	1	2	6	1	3	2	06/30/92	Rosenberg	424	93	08/21/89
	AI	5	1	2	6	2	3	8	06/30/92	Gebhard <i>et al.</i>	435	3	02/15/90
	AJ	5	1	4	7	2	8	9	09/15/92	Edelson	604	4	03/29/90
	AK	5	1	4	7	7	8	4	09/15/92	Peault	435	7.24	04/12/90
	AL	5	1	6	2	2	2	5	11/10/92	Sager <i>et al.</i>	435	240.243	07/15/91
	AM	5	1	9	2	5	3	7	03/09/93	Osband	424	85.2	08/19/91
	AN	5	2	0	2	2	5	4	04/13/93	Amiot <i>et al.</i>	435	240.242	10/11/90
	AO	5	2	2	9	1	1	5	07/20/93	Lynch	424	93	07/26/90
	AP	5	2	4	2	6	8	7	09/07/93	Tykocinski <i>et al.</i>	424	93	04/25/91
	AQ	5	2	7	7	9	0	7	01/11/94	Loria	424	93	07/24/92
	AR	5	3	1	6	7	6	3	05/31/94	Ochoa <i>et al.</i>	424	85.2	07/10/92
	AS	5	3	2	6	7	6	3	07/05/94	Gluchowski <i>et al.</i>	514	249	01/29/93
	AT	5	3	7	4	5	4	9	12/20/94	Leung	435	240.2	01/31/91
	AU	5	3	9	9	3	4	6	03/21/95	Anderson <i>et al.</i>	424	93.21	03/30/94
M/B	AV	5	3	9	9	3	4	7	03/21/95	Trentham <i>et al.</i>	424	184.1	09/25/92

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
HB	AW	5	4	0	9	8	1	3	04/24/95	Schwartz	435	7.24	09/30/93
	AX	5	4	1	1	7	4	9	05/02/95	Mayo <i>et al.</i>	424	578	12/23/92
	AY	5	4	3	7	9	9	4	08/01/95	Emerson <i>et al.</i>	435	240.2	12/10/93
	AZ	5	4	4	3	9	8	3	08/22/95	Ochoa <i>et al.</i>	435	240.2	03/21/88
	BA	5	4	5	9	0	6	9	10/17/95	Palsson <i>et al.</i>	435	289.1	01/06/94
	BB	5	4	6	6	5	7	2	11/14/95	Sasaki <i>et al.</i>	435	2	04/25/94
	BC	5	4	7	0	7	3	0	11/28/95	Greenberg <i>et al.</i>	435	172.3	08/08/94
	BD	5	4	7	6	9	9	7	12/19/95	Kaneshima <i>et al.</i>	800	2	05/17/94
	BE	5	4	9	8	5	3	7	03/12/96	Bresler <i>et al.</i>	435	235.1	03/09/94
	BF	5	5	1	2	4	4	4	04/30/96	Patard <i>et al.</i>	435	6	11/30/94
	BG	5	5	9	9	7	0	5	02/04/97	Cameron	435	378	11/16/93
	BH	5	6	0	5	8	2	2	02/25/97	Emerson <i>et al.</i>	435	172.3	12/01/94
	BI	5	6	2	2	8	5	7	04/22/97	Goffe	435	378	08/08/95
	BJ	5	6	2	7	0	7	0	05/06/97	Gruenberg	435	786.5	07/26/95
	BK	5	6	3	5	3	8	6	06/03/97	Palsson <i>et al.</i>	435	372	11/02/94
	BL	5	6	3	5	3	8	7	06/03/97	Fei <i>et al.</i>	435	378	04/03/95
	BM	5	6	3	7	4	8	1	06/10/97	Ledbetter <i>et al.</i>	435	69.6	09/13/93
	BN	5	6	4	6	0	4	3	07/08/97	Emerson <i>et al.</i>	435	373	03/10/95
	BO	5	6	5	6	4	2	1	08/12/97	Gebhard <i>et al.</i>	435	3	02/12/91
	BP	5	6	7	6	8	4	9	10/14/97	Sammons <i>et al.</i>	210	806	03/08/95
	BQ	5	7	1	8	8	8	3	02/17/98	Harlan <i>et al.</i>	424	9.2	02/17/94
	BR	5	7	2	8	5	8	1	03/17/98	Schwartz <i>et al.</i>	435	385	06/07/95
	BS	5	7	6	3	2	6	1	06/09/98	Gruenberg	435	286.5	12/05/96
HB	BT	5	7	6	3	2	6	6	06/09/98	Palsson <i>et al.</i>	435	289.1	11/07/94

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016

TECH CENTER 1600/2900

SEP 6 2002

RECEIVED


 DISCLOSURE OF PATENTS AND PUBLICATIONS FOR  
 APPLICANT'S INFORMATION DISCLOSURE  
 STATEMENT
APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
M/B	BU	5	7	6	6	9	2	0	06/16/98	Babbitt <i>et al.</i>	435	240.1	06/06/95
	BV	5	8	1	1	3	0	1	09/22/98	Cameron	435	372	08/07/96
	BW	5	8	1	4	2	9	5	09/29/98	Martin, Jr. <i>et al.</i>	424	1.29	07/13/94
	BX	5	8	4	6	8	2	7	12/08/98	Celis <i>et al.</i>	435	384	06/06/95
	BY	5	8	5	8	3	5	8	01/12/99	June <i>et al.</i>	424	130.1	06/03/94
	BZ	5	8	7	2	2	2	2	02/16/99	Chang	530	391.1	12/18/92
	CA	5	9	9	4	1	2	6	11/30/99	Steinman <i>et al.</i>	435	325	06/17/94
	CB	6	0	4	0	1	8	0	03/21/00	Johe	435	377	05/07/97
	CC	6	1	2	9	9	1	6	10/10/00	Chang	424	179.1	11/25/92
	CD	6	1	9	4	2	0	7	02/27/01	Bell <i>et al.</i>	435	377	01/30/98
	CE	6	2	0	4	0	5	8	03/20/01	Bolton	435	448	12/16/99
	CF	6	2	5	1	3	8	5	06/26/01	Terman	424	93.7	07/22/97
	CG	6	2	5	5	0	7	3	07/03/01	Cai <i>et al.</i>	435	69.1	03/16/98
M/B	CH	6	3	5	2	6	9	4	03/05/02	June <i>et al.</i>	424	93.71	03/10/95

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
M/B	CI	0	4	0	5	9	7	2	1/2/91	EP A1				
	CJ	0	4	4	0	3	7	3	08/07/91	EP A1				
	CK	0	4	4	0	3	7	3	08/07/91	EP B1				
	CL	2	8	8	3	2	0	1	04/19/99	JP B2			x	
	CM	9	0	0	5	5	4	1	05/31/90	PCT				
	CN	9	0	1	5	8	7	7	12/27/90	PCT				
M/B	CO	9	1	0	4	3	1	7	04/04/91	PCT				

EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
MB	CP	9	1	1	8	9	7	2	12/12/91	PCT				
	CQ	9	2	0	0	0	9	2	01/09/92	PCT				
	CR	9	3	1	9	7	6	7	10/14/93	PCT				
	CS	9	4	1	2	1	9	6	06/09/94	PCT				
	CT	9	4	2	2	4	8	9	10/13/94	PCT				
	CU	9	4	2	3	7	6	0	10/27/94	PCT				
	CV	9	4	2	8	9	1	2	12/22/94	PCT				
	CW	9	4	2	9	4	3	6	12/22/94	PCT				
	CX	9	5	2	9	6	7	3	11/09/95	PCT				
	CY	9	5	3	3	8	2	3	12/14/95	PCT				
	CZ	9	6	3	4	9	5	6	11/07/96	PCT				
	DA	9	6	3	4	9	7	0	11/7/96	PCT				
	DB	9	6	4	0	8	6	0	12/19/96	PCT				
	DC	9	6	4	0	8	7	6	12/19/96	PCT				
	DD	9	7	0	5	2	3	9	2/13/97	PCT				
	DE	9	7	3	1	6	4	7	09/04/97	PCT				
MB	DF	9	8	2	5	4	5	7	06/18/98	PCT				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DG	Al-Saleh <i>et al.</i> , "Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix," <i>Journal of Pathology</i> <u>184</u> : 283-290 (1998)
DH	Alberts, B. <i>et al.</i> (Eds.), <i>Molecular Biology of the Cell</i> , 3rd ed., New York: Garland Publishing, Inc., pp. 1169 (1994)

EXAMINER

3/7/05

DATE CONSIDERED

MB

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DI	Anderson <i>et al.</i> , "Cross-Linking of T3 (CD3) with T4 (CD4) enhances The proliferation of resting T lymphocytes," <i>The Journal of Immunology</i> <u>139</u> : 678-682 (1987).
DJ	Anderson <i>et al.</i> , "Crosslinking CD3 with CD2 using Sepharose-immobilized antibodies enhances T lymphocyte proliferation," <i>Cell Immunology</i> <u>115</u> : 246-256 (1988).
DK	Ashkenazi <i>et al.</i> , "A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: Increased level of soluble IL-2R and reduced protein tyrosine phosphorylation," <i>Neuroimmunomodulation</i> <u>4</u> : 49-56(1997)
DL	Asselin-Paturel <i>et al.</i> , "Quantitative analysis of Th1, Th2 and TGF- $\beta$ 1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients," <i>Journal of Cancer</i> <u>77</u> : 7-12 (1998)
DM	Autran <i>et al.</i> , "A Th0/Th2-like function of CD4 <sup>+</sup> CD7 <sup>+</sup> T helper cells from normal donors and HIV-infected patients," <i>J. Immunol.</i> <u>154</u> : 1408-1417 (1985)
DN	Banu <i>et al.</i> , "TGF- $\beta$ 1 down-regulates induced expression of both class II MHC and B7-1 on primary renal tubular epithelial cells," <i>Kidney International</i> <u>56</u> : 985-994 (1999)
DO	Baroja <i>et al.</i> "The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) provides a Helper Signal and Bypasses the Need for Accessory Cells in T-Cell Activation with Immobilized Anti-CD3 and Mitogens," <i>Cellular Immunology</i> <u>120</u> : 205-217 (1989).
DP	Baroja <i>et al.</i> "Cooperation Between an Anti-T Cell (Anti-CD28) Monoclonal Antibody and Monocyte-Produced IL-6 in the Induction of T Cell Responsiveness to IL-2," <i>The Journal of Immunology</i> <u>141</u> : 1502-1507 (1988).
DQ	Bartholeyns <i>et al.</i> , "Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer," <i>Anticancer Research</i> <u>14</u> : 2673-2676 (1994)
DR	Bellone <i>et al.</i> , "Tumor-associated transforming growth factor- $\beta$ and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients," <i>American Journal of Pathology</i> <u>155</u> (2): 537-547(1999)
DS	Benvenuto <i>et al.</i> "Enhanced production of interferon- $\gamma$ by T lymphocytes cloned from rejected kidney grafts," <i>Transplantation</i> <u>51</u> : 887-890 (1991)
DT	Benvenuto <i>et al.</i> , "Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis," <i>Clin. Exp. Immunol.</i> <u>84</u> : 97-102 (1991)
DU	Berghella <i>et al.</i> , "The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from Th1 to Th2 and back," <i>Cancer Immunology, Immunotherapy</i> <u>45</u> : 241-249 (1998)


EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DV	Bernhard <i>et al.</i> , "Generation of immunostimulatory dendritic cells from human CD34 + hematopoietic progenitor cells of the bone marrow and peripheral blood," <i>Cancer Res.</i> <u>55</u> : 1099-1104 (1995)
DW	Boiardi <i>et al.</i> , "Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-Lak) in recurrent glioblastoma patients," <i>Cancer Immunol. Immunother.</i> <u>39</u> : 193-197 (1994)
DX	Borst <i>et al.</i> , "The $\delta$ - and $\epsilon$ - chains of the human T3/T-cell receptor complex are distinct polypeptides," <i>Nature</i> <u>312</u> : 455-458 (1986).
DY	Brod <i>et al.</i> , "Restricted T cell expression of IL-2/Ifn- $\gamma$ mRNA in human inflammatory disease," <i>J. Immunol.</i> <u>147</u> : 810-815 (1991)
DZ	Broder and Walmann, "Medical Progress: The suppressor-cell network in cancer (Second of two parts)," <i>Journal of Medicine</i> <u>299</u> (24): 1335-1341 (1978)
EA	Certified English language translation of the Japanese Patent No. 2883201.
EB	Cesano <i>et al.</i> , "Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach," <i>J. Clin. Invest.</i> <u>94</u> : 1076-1084 (1994)
EC	Ceuppens and Baroja, "Monoclonal Antibodies to the CD5 Antigen Can Provide the Necessary Second Signal for Activation of Isolated Resting T Cells by Solid-Phase-Bound OKT3," <i>The Journal of Immunology</i> <u>137</u> : 1816-1821 (1986).
ED	Chang <i>et al.</i> , "Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2," <i>Journal of Clinical Oncology</i> <u>15</u> (2): 796-807 (1997)
EE	Chen <i>et al.</i> , "Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma," <i>International Journal of Cancer</i> <u>56</u> : 755-760 (1994)
EF	Chen <i>et al.</i> , "Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and cytolytic activity of lymphocytes from malignant effusions of lung cancer patients," <i>Chest</i> <u>112</u> : 960-966 (1997)
EG	Chen <i>et al.</i> , "Donor T cells can be induced to grow and survive long term <i>in vivo</i> without previous host immunosuppression," <i>J. Immunol.</i> <u>152</u> : 4767-4774 (1994)
EH	Chen <i>et al.</i> , "Regulatory T cell clone induced by oral tolerance: Suppression of autoimmune encephalomyelitis," <i>Science</i> <u>265</u> : 1237-1240 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EI	Cher <i>et al.</i> , "Two types of murine helper T cell clone," <i>Journal of Immunology</i> <u>138(11)</u> : 3688-3694 (1987)
EJ	Cherwinski <i>et al.</i> , "Two types of mouse helper T cell clone," <i>J. Exp. Med.</i> <u>166</u> : 1229-1244 (1987)
EK	Chick <i>et al.</i> , "Beta cell culture on synthetic capillaries: An artificial endocrine pancreas," <i>Science</i> <u>187</u> : 847-849 (1975)
EL	Clerici <i>et al.</i> , "Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's Disease," <i>European Journal of Cancer</i> <u>30A(10)</u> : 1464-1470 (1994)
EM	Clerici <i>et al.</i> , "A T <sub>H</sub> 1-T <sub>H</sub> 2 switch is a critical step in the etiology of HIV infection," <i>Immunology Today</i> <u>14(3)</u> : 107-111 (1993)
EN	Cohen <i>et al.</i> , "CD4 <sup>+</sup> T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection," <i>Critical Reviews in Immunology</i> <u>20</u> : 17-56 (2000)
EO	D'Orazio <i>et al.</i> , "A novel role for TGF- $\beta$ and IL-10 in the induction of immune privilege," <i>Journal of Immunology</i> <u>160</u> : 2089-2098 (1998)
EP	Damle <i>et al.</i> , "Impairment in proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2-producing cells in Hodgkin's disease," <i>Cancer Immunology, Immunotherapy</i> <u>34</u> : 205-210 (1991)
EQ	Damle <i>et al.</i> , "Differential Costimulatory Effects of Adhesion Molecules B7, ICAM-1, LFA-3, and VCAM-1 On Resting and Antigen-Primed CD4 <sup>+</sup> T Lymphocytes," <i>The Journal of Immunology</i> <u>148</u> : 1985-1992 (1992).
ER	Damle <i>et al.</i> , "Stimulation Via the CD3 and CD28 Molecules Induces responsiveness To IL-4 in CD4 <sup>+</sup> CD29 <sup>+</sup> CD45R <sup>+</sup> Memory T Lymphocytes," <i>The Journal of Immunology</i> <u>143</u> : 1761-1767 (1989)
ES	David <i>et al.</i> , "Continuous production of carcinoembryonic antigen in hollow fiber cell culture units: Brief communication," <i>J. Natl. Cancer Inst.</i> <u>60(2)</u> : 303-306 (1978)
ET	Davis, J.E. <i>et al.</i> , "Mass Transfer Between Capillary Blood and Tissues", <i>Chem. Eng. J.</i> <u>7</u> : 213-225 (1974)
EU	de Waal Malefyt <i>et al.</i> , "Direct effects of IL-10 on subsets of human CD4 <sup>+</sup> T cell clones and resting T cells," <i>Journal of Immunology</i> <u>150(11)</u> : 4754-4765 (1993)
EV	de Carli <i>et al.</i> , "Cytolytic T cells with Th1- like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy," <i>J. Clinical Endocrinol. Metabol.</i> <u>77(5)</u> : 1120-1124 (1993)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY





FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EW	De Jong <i>et al.</i> , "Maturation- and differentiation-dependent responsiveness of human CD4 <sup>+</sup> T helper subsets," <i>J. Immunol.</i> <u>149</u> : 2795-2802 (1992)
EX	De Totero <i>et al.</i> , "IL4 production and increased CD30 expression by a unique CD8 T-cell subset in B-cell chronic lymphocytic leukaemia," <i>British Journal of Haematology</i> <u>104</u> : 589-599 (1999)
EY	De Vita <i>et al.</i> , "Serum interleukin-10 is an independent prognostic factor in advanced solid tumors," <i>Oncology Reports</i> <u>7</u> : 357-361 (2000)
EZ	Del Prete <i>et al.</i> , "Purified Protein derivative of <i>Mycobacterium tuberculosis</i> and excretory-secretory antigen(s) of <i>Toxocara canis</i> expand <i>in vitro</i> human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production," <i>J. Clin. Invest.</i> <u>88</u> : 346-350 (1991)
FA	Del Prete <i>et al.</i> , "High potential to tumor necrosis factor $\alpha$ (TNF- $\alpha$ ) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: A peculiar feature of destructive thyroid autoimmunity," <i>Autoimmunity</i> <u>4</u> : 267-276 (1989)
FB	Demeure <i>et al.</i> , "Human naive CD4 T cells produce interleukin-4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions," <i>European Journal of Immunology</i> <u>25</u> : 2722-2725 (1995)
FC	Derwent #008306271 WPI Acc. No. 1990-193272/199025 (citing, WO Patent Publication WO90/05541, the parent of Japanese Patent Publication No. JP 2883201, published April 19, 1999).
FD	Dillman <i>et al.</i> , "Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma," <i>Cancer</i> <u>68</u> : 1-8 (1991)
FE	Dillman <i>et al.</i> , "Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A national biotherapy study group trial," <i>J. Clin. Oncology</i> <u>9</u> (7): 1233-1240 (1991)
FF	Ding, L. <i>et al.</i> , "Activation of CD4 <sup>+</sup> T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation)," <i>European J. of Immunology</i> <u>24</u> : 859-866 (1994).
FG	Eastcott <i>et al.</i> , "Adoptive transfer of cloned T helper cells ameliorates periodontal disease in nude rats," <i>Oral Microbiol. Immunol.</i> <u>9</u> : 284-289 (1994)
FH	Economou <i>et al.</i> , "In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes," <i>Journal of Clinical Investigation</i> <u>97</u> : 515-521 (1996)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO.  
24731-5048

SERIAL NO.  
10/071,016

APPLICANT  
GRUENBERG, Michael L.

FILING DATE  
February 7, 2002

GROUP  
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


FI	Elsässer-Beile <i>et al.</i> , "Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3 <sup>+</sup> , CD4 <sup>+</sup> , and CD8 <sup>+</sup> renal-cell-carcinoma-infiltrating lymphocytes," <i>Cancer Immunology, Immunotherapy</i> <u>48</u> : 204-208 (1999)
FJ	Elsässer-Beile <i>et al.</i> , "Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas," <i>Tumour Biology</i> <u>19</u> : 470-476 (1998)
FK	Elson <i>et al.</i> , "T cell subpopulation phenotypes in filarial infections: CD27 negativity defines a population greatly enriched for T <sub>H</sub> 2 cells," <i>Internat. Immunol.</i> <u>6</u> : 1003-1009 (1993)
FL	Emori <i>et al.</i> , "Effect of Z-100, an immunomodulator extracted from human type tubercle bacilli, on the pulmonary metastases of Lewis lung carcinoma in attempt to regulate suppressor T cells and suppressor factor, IL-4," <i>Biotherapy</i> <u>9</u> : 249-255 (1996)
FM	Englemann <i>et al.</i> , "Activation of human T lymphocyte subsets: Helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens," <i>J. Immunol.</i> <u>127</u> : 2124-2129 (1981)
FN	Fan <i>et al.</i> , "Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection," <i>Mediators of Inflammation</i> <u>7</u> : 295-297 (1994)
FO	Faradji <i>et al.</i> , "Large scale isolation of human blood monocytes by continuous flow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients," <i>J. Immunol. Meth.</i> <u>174</u> : 297-309 (1994)
FP	Figlin <i>et al.</i> , "Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor," <i>Journal of Urology</i> <u>158</u> : 740-745 (1997)
FQ	Finke <i>et al.</i> , "Characterization of a human renal cell carcinoma specific cytotoxic CD8 <sup>+</sup> T cell line," <i>Journal of Immunotherapy</i> <u>11</u> : 1-11 (1992)
FR	Finke <i>et al.</i> , "Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon- $\gamma$ secretion, and proliferation," <i>Journal of Immunotherapy with Emphasis on Tumor Immunology</i> <u>15</u> : 91-104 (1994)
FS	Fiorentino <i>et al.</i> , "Two types of mouse T helper cell," <i>J. Exp. Med.</i> <u>170</u> : 2081-2095 (1989)
FT	Firestein <i>et al.</i> , "A new murine CD4 <sup>+</sup> T cell subset with an unrestricted cytokine profile," <i>J. Immunol.</i> <u>143</u> : 518-525 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FU	Foon <i>et al.</i> , "Renal cell carcinoma treated with continuous-infusion interleukin-2 with <i>ex vivo</i> -activated killer cells," <i>J. Immunotherapy</i> <u>11</u> : 184-190 (1992)
FV	Fortis <i>et al.</i> , "Increased interleukin-10 serum levels in patients with solid tumours," <i>Cancer Letters</i> <u>104</u> : 1-5 (1996)
FW	Foulis <i>et al.</i> , "Insulinitis in type 1 (insulin-dependent) diabetes mellitus in Man-macrophages, lymphocytes, and interferon- $\mu$ containing cells," <i>J. Pathol.</i> <u>165</u> : 97-103 (1991)
FX	Fowell <i>et al.</i> , "Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4 <sup>+</sup> T cell subset that inhibits this autoimmune potential," <i>J. Exp. Med.</i> <u>177</u> : 627-636 (1993)
FY	Fowler <i>et al.</i> , "Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice," <i>Advances in Bone Marrow Purging and Processing: Fourth International Symposium</i> 533-540 (1994)
FZ	Fowler <i>et al.</i> , "Donor CD4-Enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice," <i>Blood</i> <u>84</u> (10): 3540-3549 (1994)
GA	Freedman <i>et al.</i> , "Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial," <i>J. Immunol.</i> <u>16</u> : 198-210 (1994)
GB	Friess <i>et al.</i> , "Treatment of advanced pancreatic cancer with Mistletoe: results of a pilot trial," <i>Anticancer Research</i> <u>16</u> : 915-920 (1996)
GC	Fujimoto <i>et al.</i> , "Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state," <i>Journal of Immunology</i> <u>158</u> : 5619-5626 (1997)
GD	Fujisao and Tsuda, "Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma," <i>British Journal of Haematology</i> <u>103</u> : 308-310 (1998)
GE	Funauchi <i>et al.</i> , "Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus," <i>Scandinavian Journal of Rheumatology</i> <u>27</u> : 219-224 (1998)
GF	Gabrilovich <i>et al.</i> , "Dendritic cells in antitumor immune responses," <i>Cellular Immunology</i> <u>170</u> : 111-119 (1996)
GG	Galandrini <i>et al.</i> , "Antibodies to CD44 trigger effector functions of human T cell clones," <i>J. Immunol.</i> <u>150</u> : 4225-4235 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GH	Garlie <i>et al.</i> , "T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer," <i>Journal of Immunotherapy</i> <u>22</u> : 336-345 (1999)
	GI	Gaudernack <i>et al.</i> , "Isolation of pure functionally active CD8 <sup>+</sup> T cells positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres," <i>J. Immun. Meth.</i> <u>90</u> : 179-187 (1986)
	GJ	Ghosh <i>et al.</i> , "Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth," <i>Journal of the National Cancer Institute</i> <u>87</u> (19): 1478-1483 (1995)
	GK	Goedegbuure <i>et al.</i> , "Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study," <i>J. Clin. Oncol.</i> <u>13</u> : 1939-1949 (1995)
	GL	Goedegbuure <i>et al.</i> , "Simultaneous production of T Helper-1-like Cytokines and Cytolytic activity by tumor-specific T cells in ovarian and breast cancer," <i>Cellular Immunology</i> <u>175</u> : 150-156 (1997)
	GM	Gold <i>et al.</i> , "Autolymphocyte therapy," <i>J. Surgical Res.</i> <u>59</u> : 270-286 (1995)
	GN	Gold <i>et al.</i> , "Adoptive Tumor immunotherapy using human CD4 <sup>+</sup> T-cells," <i>Br. J. Cancer</i> <u>67</u> : 865 (1993)
	GO	Gorelik <i>et al.</i> , "Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor," <i>Immunology, Immunotherapy</i> <u>39</u> : 117-126 (1994)
	GP	Grabbe <i>et al.</i> , "Dendritic cells as initiators of tumor immune responses: A Possible strategy for tumor immunotherapy," <i>Immunology Today</i> <u>16</u> : 117-121 (1995)
	GQ	Graham <i>et al.</i> , "Influenza virus-specific CD4 <sup>+</sup> T Helper Type 2 T lymphocytes do not promote recovery from experimental virus infection," <i>Journal of Experimental Medicine</i> <u>180</u> : 1273-1282 (1994)
	GR	Graham <i>et al.</i> , "The use of <i>ex vivo</i> -activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study," <i>Seminars in Urology</i> <u>11</u> : 27-34 (1993)
	GS	Grau <i>et al.</i> , "Implications of cytokines in immunopathology: Experimental and clinical data," <i>Eur. Cytokine Net.</i> <u>1</u> : 203-210 (1990)
	GT	Grimm <i>et al.</i> , "Lymphokine-activated killer cell phenomenon," <i>J. Exp. Med.</i> <u>155</u> : 1823-1841 (1982)
	GU	Gullino <i>et al.</i> , "Tissue culture on artificial capillaries," <i>Meth. Enzymol.</i> <u>58</u> : 178-184 (1979)


EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636SEP 08 2002  
TECH CENTER 1600/2900

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GV	Hager <i>et al.</i> , "Tumor-associated antigens produced by mouse mammary tumor cells in artificial capillary culture," <i>J. Natl. Cancer Inst.</i> <u>69</u> : 1359-1365 (1982)
	GW	Hammel <i>et al.</i> , "Effect of interleukin-1 $\alpha$ on the <i>in vitro</i> activation of tumor-draining lymph node cells for adoptive immunotherapy," <i>J. Immunotherapy</i> <u>16</u> : 1-12 (1993)
	GX	Han <i>et al.</i> , "A new type of CD4 <sup>+</sup> suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice," <i>Journal of Autoimmunity</i> <u>9</u> : 331-339 (1996)
	GY	Handgretinger <i>et al.</i> , "Rapid method for purification of CD56 <sup>+</sup> natural killer cells with preferential enrichment of the CD56 <sup>bright</sup> subset," <i>Journal of Clinical Laboratory Analysis</i> <u>8</u> : 443-446 (1994)
	GZ	Hansel <i>et al.</i> , "Purification of human blood eosinophils by negative selection using immunomagnetic beads," <i>Journal of Immunological Methods</i> <u>122</u> : 97-103 (1989)
	HA	Hansen <i>et al.</i> , "Monoclonal antibodies identifying a novel T-cell antigen and Ia antigen of human lymphocytes," <i>Immunogenetics</i> <u>10</u> : 247-260 (1980)
	HB	Hara <i>et al.</i> , "Human T cell activation," <i>J. Exp. Med.</i> <u>161</u> : 1513-1524 (1985)
	HC	Hara <i>et al.</i> , "Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2," <i>Japanese Journal of Cancer Research</i> <u>87</u> : 724-729 (1996)
	HD	Hauer <i>et al.</i> , "Analysis of Th1 and Th2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated <i>in vitro</i> with <i>Helicobacter pylori</i> ," <i>Journal of Clinical Pathology</i> <u>50</u> : 957-959 (1997)
	HE	Hawke <i>et al.</i> , "Stimulation of human T cells by sparse antigen captured on immunomagnetic particles," <i>J. of Immunol. Methods</i> <u>155</u> : 41-48 (1992).
	HF	Heniford <i>et al.</i> , "Interleukin-8 suppresses the toxicity and antitumor effect of interleukin-2," <i>Journal of Surgical Research</i> <u>56</u> : 82-88 (1994)
	HG	Henschler <i>et al.</i> , "Maintenance of transplantation potential in <i>ex vivo</i> expanded CD34 <sup>+</sup> - selected human peripheral blood progenitor cells," <i>Blood</i> <u>84</u> : 2898-2903 (1994)
	HH	Herberman <i>et al.</i> , "Adoptive therapy with purified CD8 cells in HIV infection," <i>AIDS/Cancer Therapies</i> , 35-44.
	HI	Hirschberg <i>et al.</i> , "Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma," <i>American Journal of Hematology</i> <u>60</u> : 143-147 (1999)


EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HJ	Ho <i>et al.</i> , "A phase 1 study of adoptive transfer of autologous CD8 <sup>+</sup> lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS," <i>Blood</i> <u>81</u> : 2093-2101 (1993)
HK	Horiguchi <i>et al.</i> , "Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells," <i>Cancer Research</i> <u>59</u> : 2950-2956 (1999)
HL	Hrouda <i>et al.</i> , "Immunotherapy of advanced prostate cancer: a phase I/II trial using <i>Mycobacterium vaccae</i> (SRL172)," <i>British Journal of Urology</i> <u>82</u> : 568-573 (1992)
HM	Hsieh <i>et al.</i> , "Differential regulation of T helper phenotype development by interleukins 4 and 10 in an $\alpha\beta$ T-cell-receptor transgenic system," <i>Proc. Natl. Acad. Sci. USA</i> <u>89</u> : 6065-6089 (1992).
HN	Huang <i>et al.</i> , "Non-small cell lung cancer-derived soluble mediators and prostaglandin E <sub>2</sub> enhance peripheral blood lymphocyte IL-10 transcription and protein production," <i>Journal of Immunology</i> <u>157</u> : 5512-5520 (1996)
HO	Huet <i>et al.</i> , "T cell activation via CD2 [T, gp50]: The role of accessory cells in activating resting T cells via CD2," <i>J. Immunol.</i> <u>137</u> : 1420-1428 (1986)
HP	Huettner <i>et al.</i> , "Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas," <i>American Journal of Pathology</i> <u>146</u> : 317-322 (1995)
HQ	Igletseme <i>et al.</i> , "Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, TH <sub>1</sub> Lymphocyte clone," <i>Regional Immunology</i> <u>5</u> : 317-324 (1993)
HR	Inagawa <i>et al.</i> , "Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions," <i>Anticancer Research</i> <u>18</u> : 3957-3964 (1998)
HS	Ito <i>et al.</i> , "Lung Carcinoma: Analysis of T Helper Type 1 and 2 cells and T Cytotoxic Type 1 and 2 cells by intracellular cytokine detection with flow cytometry," <i>Cancer</i> <u>85</u> : 2359-2367 (1999)
HT	Jacobs <i>et al.</i> , "Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix," <i>Clinical and Experimental Immunology</i> <u>111</u> : 219-224 (1998)
HU	Jacobs <i>et al.</i> , "Efficient immunoselection of cytolytic effectors with a magnetic cell sorter," <i>Research in Immunology</i> <u>144</u> : 141-150 (1993)
HV	Jensen <i>et al.</i> , "Production of anchorage-dependent cells-problems and their possible solutions," <i>Biotechnol. Bioeng.</i> <u>23</u> : 2703-2716 (1981)


EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HW	Jiang <i>et al.</i> , "Increased Intraplatelet and urinary transforming growth factor- $\beta$ in patients with multiple myeloma," <i>Acta Haematologica</i> <u>12</u> : 1-6 (1995)
HX	June <i>et al.</i> , "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", <i>Molecular and Cell Biology</i> , <u>7</u> (12): 4472-4481 (1987).
HY	Karawajew <i>et al.</i> , "A simple and sensitive method to study effects mediated by soluble lymphokines as demonstrated by the interaction of CD4+ and CD8+ cell subsets during T cell activation," <i>The Journal of Immunological Methods</i> <u>173</u> : 27-31 (1994).
HZ	Kim <i>et al.</i> , "IL-10 Production in cutaneous basal and squamous cell carcinomas," <i>Journal of Immunology</i> <u>155</u> : 2240-2247 (1995)
IA	Kitahara <i>et al.</i> , "Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432," <i>Journal of Laryngology and Otology</i> <u>110</u> : 449-453 (1996)
IB	Klimas <i>et al.</i> , "Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion," <i>AIDS</i> <u>8</u> : 1073-1081 (1994)
IC	Knazek <i>et al.</i> , "Brief communication: Formation of solid human mammary carcinoma <i>in vitro</i> ," <i>J. Natl. Cancer Inst.</i> <u>58</u> : 419-422 (1977)
ID	Knazek <i>et al.</i> , "Hormone production by cells grown <i>in vitro</i> on artificial capillaries," <i>Exp. Cell Res.</i> <u>84</u> : 251-254 (1974)
IE	Knazek <i>et al.</i> , "Cell culture on artificial capillaries: An approach to tissue growth <i>in vitro</i> ," <i>Science</i> <u>173</u> : 65-67 (1972)
IF	Knoefel <i>et al.</i> , "A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 Melanoma," <i>Journal of Interferon and Cytokine Research</i> <u>17</u> : 95-102 (1997)
IG	Kobayashi <i>et al.</i> , "A Pathogenic Role of Th2 Cells and Their Cytokine Products on the Pulmonary Metastasis of Murine B16 Melanoma," <i>Journal of Immunology</i> <u>160</u> : 5869-5873 (1998)
IH	Kobayashi <i>et al.</i> , "Inhibition of pulmonary metastasis by Z-100, an immunomodulatory lipid-arabinomannan extracted from <i>Mycobacterium Tuberculosis</i> , in mice inoculated with B16 melanoma," <i>Anti-Cancer Drugs</i> <u>8</u> : 156-163 (1997)
II	Koretz <i>et al.</i> , "Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer," <i>Arch. Surg.</i> <u>126</u> : 898-903 (1991)


EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IJ	Krüger-Krasagakes <i>et al.</i> , "Expression of interleukin 10 in human melanoma," <i>Journal of Cancer</i> <u>70</u> : 1182-1185 (1994)
IK	Kuiper <i>et al.</i> , "Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation," <i>European J. of Immunology</i> <u>24</u> (9): 1956-60 (1994).
IL	Lane <i>et al.</i> , "Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation," <i>Blood</i> <u>85</u> : 275-282 (1995)
IM	Lea <i>et al.</i> , "Characterization of human mononuclear cells after positive selection with immunomagnetic particles," <i>Scand. J. Immunol.</i> <u>23</u> : 509-519 (1986)
IN	Lea <i>et al.</i> , "Magnetic Monosized polymer particles for fast and specific fractionation of human mononuclear cells," <i>Scand. J. Immunol.</i> <u>22</u> : 207-216 (1985)
IO	Ledbetter <i>et al.</i> , "Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells," <i>J. Immunol.</i> <u>135</u> : 2331-2336 (1985)
IP	Ledbetter <i>et al.</i> , "Signal transduction through CD4 receptors: Stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor," <i>Eur. J. Immunol.</i> <u>18</u> : 525-532 (1988)
IQ	Ledbetter <i>et al.</i> , "Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression," <i>J. Immunol.</i> <u>135</u> : 1819-1825 (1985)
IR	Ledbetter <i>et al.</i> , "Antibody Binding to CD5 (Tp67) and Tp44 Cell Surface Molecules: Effects on Cyclic Nucleotides, Cytoplasmic Free Calcium, and cAMP-Mediated Suppression," <i>The Journal of Immunology</i> <u>137</u> (10): 3299-3305 (1986).
IS	Lee <i>et al.</i> , "T Helper 2-Dominant Antilymphoma Immune Response Is Associated With Fatal Outcome," <i>Blood</i> <u>90</u> : 1611-1617 (1997)
IT	Leite-De-Moraes <i>et al.</i> , "IL-4-producing NK T Cells are biased towards IFN- $\gamma$ production by IL-12. Influence of the microenvironment on the functional capacities of NK T Cells," <i>European Journal of Immunology</i> <u>28</u> : 1507-1515 (1998)
IU	Levine <i>et al.</i> , "Ex Vivo Replicative Potential of Adult Human Peripheral Blood CD4+ T Cells," <i>Transplantation Proceedings</i> <u>29</u> : 2028 (1997)
IV	Li <i>et al.</i> , "Cyclophosphamide Given After Active Specific Immunization Augments Antitumor Immunity by modulation of TH1 Commitment of CD4+ T Cells," <i>Journal of Surgical Oncology</i> <u>67</u> : 221-227 (1998)

EXAMINER

DATE CONSIDERED


3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO.  
24731-504B

SERIAL NO.  
10/071,016

APPLICANT  
GRUENBERG, Michael L.

FILING DATE  
February 7, 2002

GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IW	Liblau <i>et al.</i> , "Th1 and Th2 CD4 <sup>+</sup> T Cells in the pathogenesis of organ-specific autoimmune diseases," <i>Immunology Today</i> <u>16</u> : 34-38 (1995)
IX	Lindqvist <i>et al.</i> , "Enhanced IL-4-mediated D10.G4.1 Proliferation with suboptimal concentrations of anti-IL-4 receptor Monoclonal antibodies," <i>J. Immunol.</i> <u>150</u> : 394-398 (1993)
IY	Lowes <i>et al.</i> , "T Helper Cytoine mRNA Is Increased in Spontaneously Regressing Primary Melanomas," <i>Journal of Investigative Dermatology</i> <u>108</u> : 914-919 (1997)
IZ	Lúdvíksson <i>et al.</i> , "The effect of TGF- $\beta$ 1 on immune responses of naïve versus memory CD4 <sup>+</sup> Th1/Th2 T cells," <i>European Journal of Immunology</i> <u>30</u> : 2101-2111 (2000)
JA	Lum <i>et al.</i> "Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients," <i>Bone Marrow Transplantation</i> <u>12</u> : 565-571 (1993).
JB	Lum <i>et al.</i> , "In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen," <i>Cell. Immunol.</i> <u>72</u> : 122-129 (1982)
JC	Luyten <i>et al.</i> , "Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation," <i>J. Biol. Chem.</i> <u>264</u> (23): 13377-13380 (1989)
JD	Lynch <i>et al.</i> , "Interleukin 7 promotes long-term <i>in vitro</i> growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy <i>in vivo</i> ," <i>J. Exp. Med.</i> <u>179</u> : 31-42 (1994)
JE	Manetti <i>et al.</i> , "CD30 expression by CD8 <sup>+</sup> T cells producing type 2 helper cytokines. Evidence for large numbers of CD8 <sup>+</sup> CD30 <sup>+</sup> T cell clones in human immunodeficiency virus infection," <i>J. Exp. Med.</i> <u>180</u> : 2407-2411 (1994)
JF	Manger <i>et al.</i> , "T cell activation: Differences in the signals required for IL 2 Production by nonactivated and activated T cells," <i>J. Immunol.</i> <u>135</u> : 3669-3673 (1985)
JG	Mantovani <i>et al.</i> , "Nuova Tecnica di Purificazione Linfocitaria Per La Tipizzazione HLA," (1989) <i>Bollettino - Societa Italiana Biologia Sperimentale</i> <u>65</u> (10): 967-973 (1989)
JH	Marcus <i>et al.</i> , "The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced <i>in vivo</i> antitumor activity," <i>J. Immunotherapy</i> <u>15</u> : 105-112 (1994)
JI	Martin <i>et al.</i> , "A 44 Kilodalton Cell Surface Homodimer Regulates Interleukin 2 Production By Activated Human T Lymphocytes", <i>J. of Immunol.</i> <u>136</u> (9): 3282-3287 (1986).
JJ	Masumura <i>et al.</i> , "Characteristics and <i>in vivo</i> homing of long-term T-cell Lines and clones derived from tumor-draining lymph nodes," <i>Cancer Res.</i> <u>54</u> : 2744-2750 (1994)

EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY




FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24731-504B	SERIAL NO. 10/071,016
	APPLICANT GRUENBERG, Michael L.	
	FILING DATE February 7, 2002	GROUP 1636

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT


## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	JK	Ménétrier-Caux <i>et al.</i> , "Renal cell carcinoma induces interleukin 10 and prostaglandin E <sub>2</sub> production by monocytes," <i>British Journal of Cancer</i> <u>79</u> : 119-132 (1999)
	JL	Miller <i>et al.</i> , "Large scale <i>ex vivo</i> expansion and activation of human natural killer cells for autologous therapy," <i>Bone Marrow Transplantation</i> <u>14</u> : 555-562 (1994)
	JM	Mosmann <i>et al.</i> , "The expanding universe of T-cell subset: Th1, Th2 and more," <i>Immunology Today</i> <u>17</u> (3): 138-146 (1996)
	JN	Mosmann <i>et al.</i> , "Two types of murine helper T cell clone," <i>Journal of Immunology</i> <u>1</u> <u>136</u> : 2348-2357 (1986)
	JO	Mosmann, T.R. and R.L. Coffman, "TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties," <i>Ann. Rev. Immunology</i> <u>7</u> : 145-173 (1989)
	JP	Mosmann, T.R. and R.L. Coffman, "Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T Cells," <i>Advances in Immunology</i> <u>46</u> : 111-147 (1989)
	JQ	Mulder <i>et al.</i> , "Culture of tumor-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumor cells does not affect tumor-specificity," <i>Cancer Immunol. Immunother.</i> <u>41</u> : 293-301 (1995)
	JR	Nabel <i>et al.</i> , "An inducible transcription factor activates expression of human immunodeficiency virus in T cells," <i>Nature</i> <u>326</u> : 711-3 (1987).
	JS	Nabioullin <i>et al.</i> , "Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages," <i>Journal of Leukocyte Biology</i> <u>55</u> : 437-442 (1994)
	JT	Nagler <i>et al.</i> , "Red blood cell depletion and enrichment of CD34 <sup>+</sup> Hematopoietic progenitor cells from human umbilical cord blood using soybean agglutinin and CD34 immunoselection," <i>Exp. Hematol.</i> <u>22</u> : 1134-1140 (1994)
	JU	Nakagomi <i>et al.</i> , "Lack of Interleukin-2 (IL-2) Expression and Selective Expression of IL-10 mRNA in Human Renal Cell Carcinoma," <i>International Journal of Cancer</i> <u>63</u> : 366-371 (1995)
	JV	Nakajima <i>et al.</i> , "Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression," <i>Proc. Natl. Acad. Sci. USA</i> <u>91</u> : 7889-7893 (1994)
	JW	Nicholson <i>et al.</i> , "An Altered Peptide Ligand Mediates Immune Deviation and Prevents Autoimmune Encephalomyelitis," <i>Immunity</i> <u>3</u> : 397-405 (1995)

EXAMINER 	DATE CONSIDERED 3/7/05
--	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JX	Niessner <i>et al.</i> , "Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR)," <i>Clin. Exp. Immunol.</i> <u>101</u> : 428-435 (1995)
JY	Nijhuis <i>et al.</i> "Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies," <i>Cancer Immunol. Immunotherapy</i> <u>32</u> : 245-50 (1990).
JZ	Nishimura <i>et al.</i> , "The critical role of Th 1-dominant immunity in tumor immunology," <i>Cancer Chemotherapy and Pharmacology</i> <u>46(Suppl)</u> : S52-S61 (2000)
KA	Nishimura <i>et al.</i> , "Generation, Propagation, and Targeting of Human CD4 + Helper.Killer T Cells induced by Anti-CD3 Monoclonal Antibody Plus Recombinant IL-2," <i>J. Immunol.</i> <u>148</u> : 285-291 (1992)
KB	Nitta <i>et al.</i> , "Selective expression of interleukin-10 gene within glioblastoma multiforme," <i>Brain Research</i> <u>649</u> : 122-128 (1994)
KC	Noben-Trauth <i>et al.</i> , "Conventional, Naive CD4 + T Cells Provide an Initial Source of IL-4 During Th2 Differentiation," <i>Journal of Immunology</i> <u>165</u> : 3620-3625 (2000)
KD	O'Garra <i>et al.</i> , "Role of cytokines in determining T-lymphocyte function," <i>Immunology</i> <u>6</u> : 458-466 (1994)
KE	Oelke <i>et al.</i> , "Generation and Purification of CD8 + Melan-A-specific Cytotoxic T Lymphocytes for Adoptive Transfer in Tumor Immunotherapy," <i>Clinical Cancer Research</i> <u>6</u> : 1997-2005 (2000)
KF	Ohno <i>et al.</i> , Lectin-activated Killer cells rapidly induced by pokeweed mitogen conjugated beads and their <i>in vivo</i> antitumor effects, <i>Int. J. Immunopharmacol.</i> <u>16</u> : 761-768 (1994)
KG	Oka <i>et al.</i> , "An immunomodulatory arabinomannan extracted from <i>Mycobacterium tuberculosis</i> , Z-100, restores the balance of Th1/Th2 cell responses in tumor bearing mice," <i>Immunology Letters</i> <u>70</u> : 109-117 (1999)
KH	Okamoto <i>et al.</i> , "The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells," <i>Cancer Immunol. Immunother</i> <u>40</u> : 173-181 (1995)
KI	Okamoto <i>et al.</i> , "Local Injection of OK432 Can Augment the Th1-Type T-Cell Response in Tumor-Draining Lymph Node Cells and Increase Their Immunotherapeutical Potential," <i>International Journal of Cancer</i> <u>70</u> : 598-605 (1997)

EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO.  
24731-5048

SERIAL NO.  
10/071,016

APPLICANT  
GRUENBERG, Michael L.

FILING DATE  
February 7, 2002

GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KJ	Okarma <i>et al.</i> , "The AIS collector: A new technology for stem cell purification," <i>Advances in Bone Marrow Purging and Processing: proceedings of the Third International Symposium on Bone Marrow Purging and Processing held in San Diego, CA, October 1991</i> Worthington-White <i>et al.</i> (Eds.) New York: Wiley-Liss, Inc. pp.487-504 (1992)
KK	Okutomi <i>et al.</i> , "Clinical Effects of Adjuvant Therapy Using Z-100 (Ancer 20 Injection) for Oral Cancer - Prevention of Stomatitis and Hematopoietic Impairment," <i>Gan To Kagaku Ryoho (Japanese Journal of Cancer and Chemotherapy)</i> <u>27(1)</u> : 65-71 (2000)
KL	Onishi <i>et al.</i> , "An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma," <i>Bju International</i> <u>83</u> : 488-492 (1999)
KM	Oxholm <i>et al.</i> , "Cytokine expression in labial salivary glands from patients with primary Sjogrens syndrome," <i>Autoimmunity</i> <u>12</u> : 185-191 (1992)
KN	Pai <i>et al.</i> "Cross-linking CD28 leads to activation of 70-kDa S6 kinase," <i>European Journal of Immunology</i> <u>24(10)</u> : 2364-2368 (1994).
KO	Palliard <i>et al.</i> , "Simultaneous production of IL-2, IL-4, and IFN- $\mu$ by activated human CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell clones," <i>J. Immunol.</i> <u>141</u> : 849-855 (1988)
KP	Partington <i>et al.</i> , "A novel method of cell separation based on dual parameter immunomagnetic cell selection," <i>Journal of Immunological Methods</i> <u>223</u> : 195-205 (1999)
KQ	Pellegrini <i>et al.</i> , "Disregulation in TH1 and TH2 subsets of CD4 <sup>+</sup> T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression," <i>Cancer Immunology Immunotherapy</i> <u>42</u> : 1-8 (1996)
KR	Pierrès <i>et al.</i> , "Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation," <i>Eur. J. Immunol.</i> <u>18</u> : 685-690 (1988)
KS	Polanski <i>et al.</i> , "Differentiation of Th2 cells from precursors in RA peripheral blood," <i>Arthritis &amp; Rheumatism</i> <u>39(9 Suppl.)</u> : pS126 (1996)
KT	Poorafshar <i>et al.</i> , "MMCP-8, the first lineage-specific differentiation marker for mouse basophils. Elevated numbers of potent IL-4-producing and MMCP-8-positive cells in spleens of malaria-infected mice," <i>European Journal of Immunology</i> <u>30</u> : 2660-2668 (2000)
KU	Powrie <i>et al.</i> , "Regulatory interactions between CD45RB <sup>High</sup> and CD45RB <sup>Low</sup> CD4 <sup>+</sup> T cells are important for the balance between protective and pathogenic cell-mediated immunity," <i>J. Exp. Med.</i> <u>179</u> : 589-600 (1994)
KV	Powrie <i>et al.</i> , "Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity <i>in vivo</i> ," <i>European Journal of Immunology</i> <u>23</u> : 3043-3049 (1993)


EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2300

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	KW	Poynter <i>et al.</i> , "Activation of NK1.1 <sup>+</sup> T Cells <i>in Vitro</i> and Their Possible Role in Age-Associated Changes in Inducible IL-4 Production," <i>Cellular Immunology</i> <u>179</u> : 22-29 (1997)
	KX	Prasad <i>et al.</i> , "Nutritional and Zinc Status of Head and Neck Cancer Patients: An Interpretive Review," <i>Journal of the American College of Nutrition</i> <u>17</u> : 409-418 (1998)
	KY	Prince <i>et al.</i> , "Preparation of CD8 <sup>bright</sup> and CD8 <sup>dim</sup> lymphocyte populations using two positive selection methods in tandem," <i>Journal of Immunological Methods</i> <u>165</u> : 139-148 (1993)
	KZ	Puchetti <i>et al.</i> , "A T <sub>H</sub> 1-T <sub>H</sub> 2-like switch in candidiasis: New perspectives for therapy," <i>Trends Microbiol.</i> <u>3</u> (6): 237-240 (1995)
	LA	Punnonen <i>et al.</i> , "Cytokine Production Profiles in the Peritoneal Fluids of Patients with Malignant or Benign Gynecologic Tumors," <i>Cancer</i> <u>83</u> : 788-96 (1998)
	LB	Quayle <i>et al.</i> , "Thematoid inflammatory T-cell clones express mostly Th-1 but also Th2 and mixed (Th0-like) cytokine patterns," <i>Scand. J. Immunol.</i> <u>38</u> : 75-82 (1993)
	LC	Reinherz <i>et al.</i> , "Separation of functional subsets of human T cells by a monoclonal antibody," <i>Proc. Natl. Acad. Sci. USA</i> <u>76</u> : 4061-4065 (1979)
	LD	Renzo <i>et al.</i> , "Extracorporeal photochemistry restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma," <i>Immunology</i> <u>92</u> : 99-103 (1997)
	LE	Riddell <i>et al.</i> , "Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones," <i>Science</i> <u>257</u> : 238-241 (1992)
	LF	Riddell <i>et al.</i> , "CD8 <sup>+</sup> cytotoxic T cell therapy of cytomegalovirus and HIV infection," <i>Current Opinion in Immunology</i> <u>5</u> : 484-491 (1993)
	LG	Riddell <i>et al.</i> , "Principles for adoptive T cell therapy of human viral diseases," <i>Ann. Rev. Immunology</i> <u>13</u> : 545-586 (1995)
	LH	Robinson <i>et al.</i> , "Predominant T <sub>H</sub> 2-Like Bronchoalveolar T-Lymphocyte Population in atopic Asthma," <i>New England Journal of Medicine</i> <u>326</u> : 298-304 (1992)
	LI	Romagnani <i>et al.</i> , "Regulation of the development of type 2 T-helper cells in allergy," <i>Current Opinion in Immunology</i> <u>6</u> : 838-846 (1994)
	LJ	Romagnani <i>et al.</i> , "HIV can induce a T <sub>H</sub> 1 to T <sub>H</sub> 0 shift, and preferentially replicates in CD4 <sup>+</sup> T-cell clones producing T <sub>H</sub> 2-type cytokines," <i>60th Forum in Immunology</i> , pp. 611-617 (1994)

EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LK	Romagnani, S., "Human T <sub>H</sub> 1 and T <sub>H</sub> 2 subsets: doubt no more", <i>Immunol. Today</i> , <u>12</u> :256-257 (1991)
LL	Romani <i>et al.</i> , "Proliferating dendritic cell progenitors in human blood", <i>J. Exp. Med.</i> , <u>180</u> :83-93 (1994)
LM	Romani <i>et al.</i> , "Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance", <i>Infection and Immunity</i> , <u>59</u> :4647-4654 (1991)
LN	Rosen <i>et al.</i> , "Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells - a possible role for breast cancer-associated p43," <i>Cancer Letters</i> <u>127</u> : 129-134 (1998)
LO	Rosenberg <i>et al.</i> , "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma," <i>N. Engl. J. Med.</i> <u>319</u> : 1676-1680 (1988)
LP	Rosenberg <i>et al.</i> , "Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer," <i>N. Engl. J. Med.</i> <u>313</u> : 1485-1492 (1985)
LQ	Rosenberg <i>et al.</i> , "A progress on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone," <i>N. Engl. J. Med.</i> <u>316</u> : 889-897 (1987)
LR	Roussel <i>et al.</i> , "Predominance of a type 2 intratumoural response in fresh tumour-infiltrating lymphocytes from human gliomas," <i>Clinical and Experimental Immunology</i> <u>105</u> : 344-352 (1996)
LS	Rutzky <i>et al.</i> , "Human colon adenocarcinoma cells. III. <i>In vitro</i> organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture," <i>J. Natl. Cancer Inst.</i> <u>63</u> (4): 893-902 (1979)
LT	Sacchi <i>et al.</i> , "Induction of tumor regression in experimental model of human head and neck cancer by human A-Lak cells and IL-2," <i>Int. J. Cancer</i> , <u>47</u> : 784-791 (1991)
LU	Saed <i>et al.</i> , "Mycosis Fungoides Exhibits a TH1-Type Cell-Mediated Cytokine Profile Whereas Sezary Syndrome Expresses a Th2-Type Profile," <i>Journal of Investigative Dermatology</i> <u>103</u> : 29-33 (1994)
LV	Salgaller <i>et al.</i> , "Recognition of multiple epitopes in the human melanoma antigen gp100. by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides," <i>Cancer Res.</i> <u>55</u> : 4972-4979 (1995)


EXAMINER

DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LW	Saoudi <i>et al.</i> , "TH2 activated cells prevent experiential autoimmune unweoretinitis, a TH1-dependent autoimmune disease," <i>Eur. J. Immunol.</i> <u>23</u> : 3096-3103 (1993)
LX	Sasama <i>et al.</i> , "Effect of IL-4, IFN- $\gamma$ and IL-12 on Cytokine Production from Human CD45RA and CD45RO CD4 T Cell Precursors," <i>International Archives of Allergy and Immunology</i> <u>117</u> : 255-262 (1998)
LY	Sato <i>et al.</i> , "Impaired Production of TH1 Cytokines and Increased Frequency of Th2 Subsets in PBMC from Advanced Cancer Patients," <i>Anticancer Research</i> <u>18</u> : 3951-3956 (1998)
LZ	Saxton <i>et al.</i> , "Adoptive Transfer of Anti-CD3-Activated CD4+ T Cells Plus Cyclophosphamide and Liposome-Encapsulated Interleukin-2 Cure Murine MC-38 and 3LL Tumors and Establish Tumor-Specific Immunity," <i>Blood</i> <u>89</u> : 2529-2536 (1997)
MA	Schoof <i>et al.</i> , "CD4+ T Cell Clones Isolated from Human Renal Cell Carcinoma Possess the Functional Characteristics of the Th2 Helper Cells," <i>Cellular Immunology</i> <u>150</u> : 114-123 (1993)
MB	Scott <i>et al.</i> , "The role of T-cell subsets and cytokines in the regulation of infection," <i>Immunology Today</i> , <u>12</u> : 346-348, (1991).
MC	Scott <i>et al.</i> , "Role of Cytokines and CD4+ T-Cell Subsets in the Regulation of Parasite Immunity and Disease", <i>Immunol. Rev.</i> <u>112</u> : 161-182 (1989)
MD	Scouten <i>et al.</i> "Reversible Immobilization of Antibodies on Magnetic Beads," <i>Analytical Biochem.</i> <u>205</u> : 313-318 (1992).
ME	Seder <i>et al.</i> , "Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon $\mu$ production and diminishes interleukin 4 inhibition of such priming," <i>Proc. Natl. Acad. Sci. USA</i> <u>90</u> : 10188-10192 (1993)
MF	Sedlmayr <i>et al.</i> , "Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells," <i>J. Immunotherapy</i> <u>10</u> : 336-346 (1991)
MG	Serrano <i>et al.</i> , "The Patterns of IL2, IFN- $\gamma$ , IL4 and IL5 Gene Expression in Hodgkin's Disease and Reactive Lymph Nodes Are Similar," <i>Haematologica</i> <u>82</u> : 542-549 (1997)
MH	Shanafelt <i>et al.</i> , "Costimulatory signals can selectively modulate cytokine production by subsets of CD4+ T cells," <i>J. Immunol.</i> <u>154</u> : 1684-1690 (1995).
MI	Sher <i>et al.</i> , "Role of T-Cell Derived Cytokines in the Downregulation of Immune Responses in Parasitic and Retroviral Infection", <i>Immunol. Rev.</i> <u>127</u> : 183-204 (1992)

EXAMINER

DATE CONSIDERED

3/2/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	MJ	Shimizu <i>et al.</i> , "Costimulation of proliferative responses of resting CD4 <sup>+</sup> T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin," <i>J. Immunol.</i> <u>145</u> : 59-67 (1990)
	MK	Shinomiya <i>et al.</i> , "Anti-Metastatic Activity Induced by the <i>In Vivo</i> Activation of Purified Protein Derivative (PPD)- Recognizing Th1 Type CD4 <sup>+</sup> T Cells," <i>Immunobiology</i> <u>193</u> : 439-455 (1995)
	ML	Shurin <i>et al.</i> , "Th1/TH2 balance in cancer, transplantation and pregnancy," <i>Springer Seminars in Immunopathology</i> <u>21</u> : 339-359 (1999)
	MM	Simon <i>et al.</i> , "Divergent T-cell cytokine patterns in inflammatory arthritis," <i>Proc. Natl. Acad. Sci. USA</i> <u>91</u> : 8562-8566 (1994)
	MN	Singh <i>et al.</i> , "Cutting Edge: Activation of NK T Cells by CD1 and $\alpha$ -Galactosylceramide Directs Conventional T Cells to the Acquisition of a Th2 Phenotype," <i>Journal of Immunology</i> <u>163</u> : 2373-2377 (1999)
	MO	Smith <i>et al.</i> , "Production of interleukin-10 by Human Bronchogenic Carcinoma," <i>American Journal of Pathology</i> <u>145</u> (1): 18-25 (1994)
	MP	Spertini <i>et al.</i> , "Signals delivered via MHC class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells," <i>J. Immunol.</i> <u>149</u> : 65-70 (1992)
	MQ	Springer <i>et al.</i> , "Adhesion receptors of the immune system," <i>Nature</i> <u>346</u> : 425-434 (1990)
	MR	Sredni <i>et al.</i> , "Predominance of TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS101," <i>Journal of the National Cancer Institute</i> <u>88</u> (18): 1276-84 (1996)
	MS	Sredni <i>et al.</i> , "The Protective Role of the Immunomodulator AS101 Against Chemotherapy-Induced Alopecia Studies on Human and Animal Models," <i>International Journal of Cancer</i> <u>65</u> : 97-103 (1996)
	MT	Sredni <i>et al.</i> , "Bone Marrow-Sparing and Prevention of Alopecia by AS101 in Non-Small-Cell Lung Cancer Patients Treated With Carboplatin and Etoposide," <i>Journal of Clinical Oncology</i> <u>13</u> (9): 2342-2353 (1995)
	MU	Stanciu <i>et al.</i> , "Production of IL-8 and IL-4 by positively and negatively selected CD4 <sup>+</sup> and CD8 <sup>+</sup> human T cells following a four step cell separation method including magnetic cell sorting (MACS)," <i>Journal of Immunological Methods</i> <u>187</u> : 107-115 (1996)
	MV	Sugie <i>et al.</i> , "Stimulation of NK-like YT cells via leukocyte function-associated antigen (LFA)-1," <i>J. Immunol.</i> <u>154</u> : 1691-1698 (1995)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO.  
24731-504B

SERIAL NO.  
10/071,016

APPLICANT  
GRUENBERG, Michael L.

FILING DATE  
February 7, 2002

GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MW	Swabb <i>et al.</i> , "Diffusion and convection in normal and neoplastic tissues," <i>Cancer Res.</i> <u>34</u> : 2814-2822 (1974)
MX	Sznol, M and W.J. Urba, "Adoptive immunotherapy," Chapter 13 in <i>Cancer Chemotherapy and Biological Responses Modifiers</i> , Pinedo, H.M. <i>et al.</i> (Eds.) Amsterdam, New York: Elsevier <u>14</u> : 227-248 (1993)
MY	Tabata <i>et al.</i> , "Th2 Subset Dominance among Peripheral Blood T Lymphocytes in Patients with Digestive Cancers," <i>American Journal of Surgery</i> <u>177</u> : 203-208 (1999)
MZ	Takahashi <i>et al.</i> , "Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion," <i>Jpn. J. Cancer Res.</i> <u>86</u> : 861-866 (1995)
NA	Takeuchi <i>et al.</i> , "Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma," <i>Cancer Immunol Immunother</i> <u>43</u> : 375-381 (1997)
NB	Tamura <i>et al.</i> , "T cell activation through TCR/CD3 complex IL-2 production of T cell clones stimulated with anti-CD3 without cross-linkage," <i>J. Immunol.</i> <u>48</u> : 2370-2377 (1992)
NC	Tanaka <i>et al.</i> , "Flow Cytometric Analysis of Helper T Cell Subsets (Th1 and Th2) in Healthy Adults," <i>Rinsho Byori Japanese Journal of Clinical Pathology</i> <u>46</u> : 1247-1251 (1998)
ND	Tax <i>et al.</i> , "Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells," <i>Nature</i> <u>304</u> : 445-447 (1983)
NE	Tendler <i>et al.</i> , "Abnormal Cytokine Expression in Sezary And Adult T-Cell Leukemia Cells Correlates with the Functional Diversity between These T-Cell Malignancies," <i>Cancer Research</i> <u>54</u> : 4430-4435 (1994)
NF	Thanhäuser <i>et al.</i> , "The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells," <i>Cancer Immunology, Immunotherapy</i> <u>40</u> : 103-108 (1995)
NG	Thompson <i>et al.</i> , "Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma," <i>J. Clin. Oncol.</i> <u>10</u> : 960-968 (1992)
NH	Thygesen <i>et al.</i> , "Immunity to experimental <i>Salmonella typhimurium</i> infections in rats," <i>APMIS</i> <u>102</u> : 489-494 (1994)
NI	To <i>et al.</i> , "Therapeutic Efficacy of Th1 and TH2 L-selectin-CD4 + Tumor-Reactive T Cells," <i>Laryngoscope</i> <u>110</u> : 1648-1654 (2000)

EXAMINER

3/7/05

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-504BSERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 6 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


	NJ	Torpey III <i>et al.</i> , "Effects of adoptive immunotherapy with autologous CD8 + T Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity," <i>Clinical Immunol. Immunopathol.</i> <u>68</u> : 263-272 (1993)
	NK	Toso, J.F. <i>et al.</i> , "MAGE-1-Specific Precursor Cytotoxic T-Lymphocytes Present among Tumor-Infiltrating Lymphocytes from a Patient with Breast Cancer: Characterization and Antigen-Specific Activation", <i>Cancer Res.</i> , <u>56</u> : 16-20 (1996)
	NL	Turner <i>et al.</i> , "Human T cells from autoimmune and normal individuals can produce tumor necrosis factor," <i>Eur. J. Immunol.</i> <u>17</u> : 1807-1814 (1987)
	NM	Tze <i>et al.</i> , "Long-term survival of adult rat islets of Langerhans in artificial capillary culture units," <i>Diabetes</i> , <u>26</u> : 185-191 (1977)
	NN	Urban <i>et al.</i> , "The importance of Th2 cytokines in protective immunity to nematodes," <i>Immunological Reviews</i> , <u>127</u> : 205-220 (1992)
	NO	Urdahl <i>et al.</i> "Accessory Cell-derived Costimulatory Signals Regulate T Cell Proliferation," <i>Ann. N.Y. Acad. Sci.</i> <u>636</u> : 33-42 (1991).
	NQ	Utsugi <i>et al.</i> , "Prevention of recurrent diabetes in syngeneic islet-transplanted NOD Mice by transfusion of autoreactive T lymphocytes," <i>Transplantation</i> <u>57</u> : 1799-1804 (1994)
	NR	Van Lier <i>et al.</i> , "Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen," <i>J. Immunol.</i> <u>139</u> : 1589-1596 (1987)
	NS	Van Lunzen <i>et al.</i> , "Investigations on autologous T-cells for adoptive immunotherapy of AIDS," Chapter 6 in <i>Cell Activation and Apoptosis in HIV Infection</i> , Andrieu, J.M and Lu, W. (Eds.) New York: Plenum Press, pp. 57-70 (1995)
	NT	Van Wauwe <i>et al.</i> "OKT3: A Monoclonal Anti-Human T Lymphocyte Antibody With Potent Mitogenic Properties," <i>The Journal of Immunology</i> <u>124</u> (6): 2708-2713 (1980)
	NU	Vandenberghe <i>et al.</i> , "Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: Evidence for signal transduction through CD5," <i>Eur. J. Immunol.</i> <u>21</u> : 251-259 (1991)
	NV	Von Fliedner <i>et al.</i> "Production of Tumor Necrosis Factor- $\alpha$ by Naive Or Memory T Lymphocytes Activated via CD28," <i>Cellular Immunology</i> <u>139</u> : 198-207 (1992).
	NW	Vowels <i>et al.</i> , "Th2 Cytokine mRNA Expression in Skin in Cutaneous T-Cell Lymphoma," <i>Journal of Investigative Dermatology</i> <u>103</u> : 669-673 (1994)
	NX	Wang <i>et al.</i> , "Early IL-4 Production Driving Th2 Differentiation in a Human in Vivo Allergic Model is Mast Cell Derived," <i>Clinical Immunology</i> <u>90</u> : 47-54 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


	NY	Wang <i>et al.</i> , "Selective Cytokine Gene Expression in Renal Cell Carcinoma Tumor Cells and Tumor-Infiltrating Lymphocytes," <i>International Journal of Cancer</i> <u>61</u> : 780-785 (1995)
	NZ	Weber <i>et al.</i> "Activation Through CD3 Molecule Leads to Clonal Expansion of All Human Peripheral Blood T Lymphocytes: Functional Analysis of Clonally Expanded Cells, The <i>Journal of Immunology</i> <u>135</u> (4): 2337-2342 (1985).
	OA	Weber <i>et al.</i> , "Effects of a Standardized Mistletoe Preparation on Metastatic B16 Melanoma Colonization in Murine Lungs", <i>Arzneimittel-Forschung</i> , <u>48</u> :497-502 (1998)
	OB	Werz <i>et al.</i> , "Purification of transforming growth factor beta1 from human platelets", <i>Pharmazie</i> , <u>51</u> :893-896 (1996)
	OC	Whiteside <i>et al.</i> , "Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus", <i>Blood</i> , <u>81</u> :2085-2092 (1993)
	OD	Wolf <i>et al.</i> , "Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries", <i>Trans Amer Soc Artif Int Organs</i> , <u>21</u> :16-27 (1975)
	OE	Wong <i>et al.</i> , "TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8+ T Cell Response", <i>J Immunol</i> , <u>162</u> :2251-2258 (1999)
	OF	Yamamura <i>et al.</i> , "Local Expression of Antiinflammatory Cytokines in Cancer", <i>Journal of Clinical Investigation</i> , <u>91</u> :1005-1010 (1993)
	OG	Yamamura <i>et al.</i> , Erratum: In reference to: "Defining Protective Responses to Pathogens: Cytokine Profiles in Leprosy Lesions" by Yamamura <i>et al.</i> (11 Oct., p. 277; corrected sequence), <i>Science</i> , <u>255</u> :12 (1992)
	OH	Yamamura <i>et al.</i> , "Defining Protective Responses to Pathogens: Cytokine Profiles in Leprosy Lesions", <i>Science</i> , <u>254</u> :277-279 (1991)
	OI	Yang <i>et al.</i> , "In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation", <i>J Immunol</i> , <u>155</u> :3897-3903 (1995)
	OJ	Yang <i>et al.</i> , "Default development of cloned human naive CD4 T cells into interleukin-4- and interleukin-5- producing effector cells", <i>Eur J Immunol</i> , <u>25</u> :3517-3520 (1995)
	OK	Yannelli <i>et al.</i> , "The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer", <i>J Immunol Meth</i> , <u>139</u> :1-16 (1991)
	OL	Yoon <i>et al.</i> , "Prophylactic effect of Korean mistletoe ( <i>Viscum album coloratum</i> ) extract on tumor metastasis is mediated by enhancement of NK cell activity", <i>International Journal of Immunopharmacology</i> , <u>20</u> :163-172 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
24731-5048SERIAL NO.  
10/071,016APPLICANT  
GRUENBERG, Michael L.FILING DATE  
February 7, 2002GROUP  
1636

TECH CENTER 1600/2900

SEP 10 6 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

OM	Zhang <i>et al.</i> , "T-cell cytokine responses in human infection with <i>Mycobacterium tuberculosis</i> ", <i>Infect Immun</i> , 63(8): 3231-3234 (1995)
ON	Zitvogel <i>et al.</i> , "Therapy of Murine Tumors with Tumor Peptide-pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-associated Cytokines", <i>J Exp. Med.</i> , 183:87-97 (1996)

EXAMINER


DATE CONSIDERED

3/7/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	Docket Number 549172000220	Application Number 10/071.016
	Applicant Michael C. GRUENBERG	
	Filing Date February 7, 2002	Group Art Unit 1644
	Mailing Date March <u>23</u> , 2004	



## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
<i>MB</i>	1.	10/2001	2001/0031253	Gruenberg	424	93.1	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
<i>MB</i>	2.	International Search Report, mailed on December 23, 2003, for PCT patent application no. PCT/US03/29612, 4 pages.

EXAMINER:

DATE CONSIDERED:

*3/7/05*

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	Docket Number 549172000220	Application Number 10/071,016
	Applicant Micheal L. Gruenberg	
	Filing Date February 7, 2002	Group Art Unit 1636
	Mailing Date July 18, 2003	

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
----------------------	-------------	------	--------------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
----------------------	-------------	------	--------------	---------	-------	----------	-----------------------

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
M/S	1.	Helbert, et al. (1997) <i>Clinical &amp; Experimental Immunology</i> 107(2):300-305. Database SCISEARCH on DIALOG, No. 055535566.

RECEIVED

JUL 24 2003

TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

3/7/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

sd- 156157

PTO/SB/08 (2-92)